CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy (ESIT) platform to translate and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases, today announced that Chief Executive Officer, Leslie Williams will participate on a panel and provide a company presentation at the 2018 BIO International Convention, occurring June 4-7, 2018 in Boston, MA.
Ms. Williams and a panel of experts will discuss approaches and advancements made in the non-oncology immunotherapy space. In addition, Ms. Williams will provide a corporate update presentation as the company prepares to enter Phase 2 trials for lead candidate, Nexvax2®, a vaccine in development for the treatment of celiac disease.
Details of the panel and presentation are as follows:
Panel Title: Immuno_________ (Fill in the Blank) – Translating
Immunological Insights from Oncology to Other Disease Areas
Date:
Tuesday, Jun 5, 2018
Time: 1:45 PM–2:45 PM ET
Location:
Room 210B, Level 2
Track: Next Generation Biotherapeutics
Presentation Date: Wednesday, June 6, 2018
Time: 2:30
PM–2:45 PM ET
Location: Company Presentation Theatre 3,
Level 0
About Nexvax2®
Nexvax2®
is the most advanced therapeutic approach for celiac disease in clinical
development today that targets the fundamental cause of the disease; the
loss of immune tolerance to gluten. Nexvax2 is a therapeutic vaccine
that reprograms the T-cells responsible for the symptoms of celiac
disease to stop triggering a pro-inflammatory response. Nexvax2 intends
to protect patients with celiac disease against inadvertent exposure to
gluten.
About ImmusanT, Inc.
ImmusanT is a privately held
biotechnology company focused on protecting patients with celiac disease
against the effects of gluten. By harnessing new discoveries in
immunology, ImmusanT aims to improve diagnosis and medical management of
celiac disease by protecting against the effects of gluten exposure
while patients maintain a gluten-free diet. The company is developing Nexvax2®,
a therapeutic vaccine for celiac disease, and diagnostic and monitoring
tools to improve celiac disease management. ImmusanT’s targeted
immunotherapy discovery platform can be applied to a variety of
autoimmune diseases. To learn more about ImmusanT, visit www.ImmusanT.com,
or follow ImmusanT
on Twitter.
